Abstract

STANDARDISATION OF SHALAPARNI (DESMODIUM GANGETICUM DC.) AND EVALUATION OF ITS ANTI-OXIDANT ACTIVITY WITH SPECIAL REFERENCE TO ARDHAVABHEDAKA (MIGRAINE)

*Vd. Sonali S. Gore (Final Year M.D - Ayu.), Dr. Shreedevi Huddar, M.D (AYU.), Dr. N.S. Ullegaddi, M.D (AYU.)

.

Abstract

Ardhavabhedak (Migraine) is a common clinical problem characterized by episodic attacks of head pain and associated symptoms such as nausea, sensitivity to light, sound, or head movement. It is generally thought of as a headache problem, but it has become apparent inrecent years that many patients suffer symptoms from Migraine, which do not have severe headaches as a dominant symptom which is mainly due to oxidative stress. The number of people suffering with atypical forms of Migraine is unknown. Females are 3 times more likely to have Migraine than males. Although any personcan have Migraine at any age, Migraine is most common between ages 30 and 50. It isa common condition with a prevalence of 17.6% in females and 5.7% in males; however, this condition is undertreatedand under-diagnosed worldwide. Treatment of Migraine has not only medical but also serious economic and social implications. Thus, primary-care physicians should be well versed in the diagnosis and treatment of Migraine. The objectives of the study were to standardize Shalaparni and to assess the effect of Shalaparni Kwatha and nasya alone, alongwith the Tab. Amitriptyline combined effect and Tab. Amitriptyline in the management of Ardhavabhedaka.

Keywords: Ardhavabhedak, Shalaparni Kwatha, Amytryptyline, Migraine.